197 related articles for article (PubMed ID: 21547576)
61. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
62. Contrast-Enhanced Mammographic Features of In Situ and Invasive Ductal Carcinoma Manifesting Microcalcifications Only: Help to Predict Underestimation?
Cheung YC; Chen K; Yu CC; Ueng SH; Li CW; Chen SC
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503181
[TBL] [Abstract][Full Text] [Related]
63. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Tsai WC; Chu CH; Yu CP; Sheu LF; Chen A; Chiang H; Jin JS
Dis Markers; 2008; 24(2):89-99. PubMed ID: 18219094
[TBL] [Abstract][Full Text] [Related]
64. Overall survival is improved when DCIS accompanies invasive breast cancer.
Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
[TBL] [Abstract][Full Text] [Related]
65. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
66. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
67. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
Tamimi RM; Baer HJ; Marotti J; Galan M; Galaburda L; Fu Y; Deitz AC; Connolly JL; Schnitt SJ; Colditz GA; Collins LC
Breast Cancer Res; 2008; 10(4):R67. PubMed ID: 18681955
[TBL] [Abstract][Full Text] [Related]
68. Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea.
Lee J; Oh M; Ko S; Park C; Lee ES; Kim HA; Jung Y; Lee J;
Breast Cancer (Auckl); 2019; 13():1178223418825134. PubMed ID: 30728717
[TBL] [Abstract][Full Text] [Related]
69. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
70. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
[TBL] [Abstract][Full Text] [Related]
71. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
72. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast.
Werner M; Mattis A; Aubele M; Cummings M; Zitzelsberger H; Hutzler P; Höfler H
Virchows Arch; 1999 Nov; 435(5):469-72. PubMed ID: 10592049
[TBL] [Abstract][Full Text] [Related]
73. Amplicons in breast cancers analyzed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Inokuchi M; Horike SI; Kawashima H; Ishikawa S; Ikeda H; Nakamura R; Oyama T; Dobashi Y
Hum Pathol; 2019 Mar; 85():33-43. PubMed ID: 30385370
[TBL] [Abstract][Full Text] [Related]
74. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
75. Progression Potential of Ductal Carcinoma in situ Assessed by Genomic Copy Number Profiling.
Kitamura M; Nakayama T; Mukaisho KI; Mori T; Umeda T; Moritani S; Kushima R; Tani M; Sugihara H
Pathobiology; 2019; 86(2-3):92-101. PubMed ID: 30332671
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
[TBL] [Abstract][Full Text] [Related]
77. Progression of heterogeneous breast tumors.
Subramanian B; Axelrod DE
J Theor Biol; 2001 May; 210(1):107-19. PubMed ID: 11343435
[TBL] [Abstract][Full Text] [Related]
78. P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma.
Shamloula MM; El-Shorbagy SH; Saied EM
J Egypt Natl Canc Inst; 2007 Sep; 19(3):202-10. PubMed ID: 19190693
[TBL] [Abstract][Full Text] [Related]
79. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
80. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
